Acute Myeloid Leukemia (AML) KOL Interview - US, South

An interview with a US-based key opinion leader (KOL) in which they provide insights into current prescribing habits, key marketed brands and their placement in the treatment algorithm, and expectations for late-phase pipeline therapies for AML. Key assets highlighted include Venclexta, Idhifa, Tibsovo, magrolimab, quizartinib, crenolanib, gilteritinib, and uproleselan.